Latest filing published 02 Oct 2025 for Immuneering Corp, €5,937.
Filing timeline
BuySaleInsider track record
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Michael Bookman: trading record in brief
Michael Bookman is a declared insider of Immuneering Corp (senior executive), with filings sourced from SEC (Form 4). In total, 4 filings cover trades dated from 3 August 2021 to 1 October 2025.
Purchases make up the whole of the open-market record (3 purchases, €28k). Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 1 share grant. So far in 2025, the count stands at 1 purchase and no sales.
In size, the median ticket on the buying side is €5,937. Clusters matter here: 3 out of 3 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.
The record was last updated on 2 October 2025 with an open-market purchase (€5,937) in Immuneering Corp. The median gap between a trade and its publication by SEC (Form 4) is 1 day. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Michael Bookman
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,020 shares@ US$6.829919.5% of flowClass A Common StockSEC:0001790340-25-000121:0Canonical exit: 30 Dec 2025 (T+90)
- 1,448 shares@ US$1.625.1% of flowClass A Common StockSEC:0001790340-24-000032:0
- 1,000 shares@ US$4.8815.2% of flowClass A Common StockSEC:0001415889-22-005253:0Canonical exit: 15 Aug 2022 (T+90)
- 1,402 shares@ US$15.0058.2% of flowClass A Common StockSEC:0001104659-21-099728:0Canonical exit: 1 Nov 2021 (T+90)
4 of 4 declarations
